Human fibrinogen concentrate - LFB Biomedicaments

Drug Profile

Human fibrinogen concentrate - LFB Biomedicaments

Alternative Names: Clottafact; FGTW; FibCLOT; Fibrinogen - LFB Biomedicaments

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Innsbruck Medical University; LFB Biomedicaments
  • Developer LFB Biomedicaments
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Blood proteins; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia; Blood coagulation disorders

Most Recent Events

  • 24 Aug 2016 No recent reports on development identified - Preregistration for Coagulation disorders in Turkey (IV)
  • 05 Apr 2016 Registered for Afibrinogenaemia in United Kingdom (IV) (MHRA website)
  • 27 Jan 2016 Registered for Afibrinogenaemia in Denmark (IV) through decentralised procedure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top